Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.

Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A, Izumihara R, Miya A, Kameda H, Cho KY, Atsumi T, Miyoshi H

Journal of diabetes research19 Jan 2022Cited by 9 (Europe PMC)

PMID35097130PMCIDPMC8793345DOI10.1155/2022/5603864PepBankPUB-35097130

Download PDF PubMedAsk about this study

Jump to 5 results

Summary

Incretins reduce glycemic variability (GV) in patients with type 2 diabetes, but it is unknown whether switching from a combination of basal insulin and a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) improves GV. We performed an exploratory prospective observational study to compare the effect of IDegLira and the combination on GV. We recruited hospitalized patients with type 2 diabetes who had stable glycemic control with insulin degludec (≤16 units/day) and taking a DPP-4 inhibitor. GV was analyzed using continuous glucose monitoring (CGM) before and after switching the medication to IDegLira. The principal endpoint was the change in mean amplitude of glycemic excursions (MAGE). Other indices of GV and CGM parameters were analyzed as the secondary endpoints. Fifteen participants were enrolled and 12 completed the study. In these participants, the DPP-4 inhibitor and insulin degludec were discontinued, and the equivalent dose of IDegLira was commenced. Switching to IDegLira significantly improved MAGE from 74.9 (60.3, 97.7) mg/dL to 64.8 (52.0, 78.2) mg/dL (P < 0.05), as well as other indices of GV and 24-hour mean blood glucose concentration. Analysis of the ambulatory glucose profile showed marked reductions in postprandial glucose concentration. Nocturnal glucose concentration was similar under the two treatment regimens. IDegLira improved GV as well as the mean and the postprandial glucose concentration by switching from insulin degludec plus DPP-4 inhibitor combination. IDegLira might be beneficial for patients being treated with low-dose basal insulin.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In hospitalized adults with type 2 diabetes, switching from insulin degludec plus a DPP-4 inhibitor to insulin degludec/liraglutide (IDegLira) lowered MAGE from 74.9 to 64.8 mg/dL.
In plain wordsIn hospitalized adults with type 2 diabetes, switching to a degludec/liraglutide combination reduced swings in blood glucose.
Peptide
Liraglutide
Outcome
DecreaseMean amplitude of glycemic excursions (MAGE)
Study
n = 12
Comparator
Insulin degludec plus DPP-4 inhibitor
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
MAGE before switch
74.9 mg/dL
insulin degludec plus DPP-4 inhibitor
MAGE after switch
64.8 mg/dL
IDegLira
Source sentences
Summary
Switching to IDegLira significantly improved MAGE from 74.9 (60.3, 97.7) mg/dL to 64.8 (52.0, 78.2) mg/dL (P < 0.05), as well as other indices of GV and 24-hour mean blood glucose concentration.
2 context sentences(design, population, supporting numbers)
Summary · context
We recruited hospitalized patients with type 2 diabetes who had stable glycemic control with insulin degludec (≤16 units/day) and taking a DPP-4 inhibitor.
Summary · context
Fifteen participants were enrolled and 12 completed the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3509713001
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In hospitalized adults with type 2 diabetes, switching to IDegLira improved other indices of glycemic variability.
In plain wordsIn hospitalized adults with type 2 diabetes, switching to a degludec/liraglutide combination improved other measures of glucose swings.
Peptide
Liraglutide
Outcome
DecreaseOther indices of glycemic variability
Study
n = 12
Comparator
Insulin degludec plus DPP-4 inhibitor
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
as well as other indices of GV and 24-hour mean blood glucose concentration.
2 context sentences(design, population, supporting numbers)
Summary · context
We recruited hospitalized patients with type 2 diabetes who had stable glycemic control with insulin degludec (≤16 units/day) and taking a DPP-4 inhibitor.
Summary · context
Fifteen participants were enrolled and 12 completed the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3509713002
03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In hospitalized adults with type 2 diabetes, switching to IDegLira improved 24-hour mean blood glucose.
In plain wordsIn hospitalized adults with type 2 diabetes, switching to a degludec/liraglutide combination improved average blood glucose over 24 hours.
Peptide
Liraglutide
Outcome
Decrease24-hour mean blood glucose
Study
n = 12
Comparator
Insulin degludec plus DPP-4 inhibitor
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
as well as other indices of GV and 24-hour mean blood glucose concentration.
2 context sentences(design, population, supporting numbers)
Summary · context
We recruited hospitalized patients with type 2 diabetes who had stable glycemic control with insulin degludec (≤16 units/day) and taking a DPP-4 inhibitor.
Summary · context
Fifteen participants were enrolled and 12 completed the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3509713003
04HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In hospitalized adults with type 2 diabetes, the ambulatory glucose profile showed marked reductions in postprandial glucose after switching to IDegLira.
In plain wordsIn hospitalized adults with type 2 diabetes, switching to a degludec/liraglutide combination clearly lowered blood glucose after meals.
Peptide
Liraglutide
Outcome
DecreasePostprandial glucose concentration
Study
n = 12
Comparator
Insulin degludec plus DPP-4 inhibitor
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Analysis of the ambulatory glucose profile showed marked reductions in postprandial glucose concentration.
2 context sentences(design, population, supporting numbers)
Summary · context
We recruited hospitalized patients with type 2 diabetes who had stable glycemic control with insulin degludec (≤16 units/day) and taking a DPP-4 inhibitor.
Summary · context
Fifteen participants were enrolled and 12 completed the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3509713004
05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In hospitalized adults with type 2 diabetes, nocturnal glucose was similar under IDegLira and under insulin degludec plus a DPP-4 inhibitor.
In plain wordsIn hospitalized adults with type 2 diabetes, night-time glucose was similar with the degludec/liraglutide combination and with the earlier treatment.
Peptide
Liraglutide
Outcome
No significant changeNocturnal glucose concentration
Study
n = 12
Comparator
Insulin degludec plus DPP-4 inhibitor
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Nocturnal glucose concentration was similar under the two treatment regimens.
2 context sentences(design, population, supporting numbers)
Summary · context
We recruited hospitalized patients with type 2 diabetes who had stable glycemic control with insulin degludec (≤16 units/day) and taking a DPP-4 inhibitor.
Summary · context
Fifteen participants were enrolled and 12 completed the study.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3509713005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.